PL1802581T3 - 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-alkoksy-7-etynylo-3-chinolinokarbonitryle do leczenia urazów niedokrwiennych - Google Patents
4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-alkoksy-7-etynylo-3-chinolinokarbonitryle do leczenia urazów niedokrwiennychInfo
- Publication number
- PL1802581T3 PL1802581T3 PL05820982T PL05820982T PL1802581T3 PL 1802581 T3 PL1802581 T3 PL 1802581T3 PL 05820982 T PL05820982 T PL 05820982T PL 05820982 T PL05820982 T PL 05820982T PL 1802581 T3 PL1802581 T3 PL 1802581T3
- Authority
- PL
- Poland
- Prior art keywords
- quinolinecarbonitriles
- ethynyl
- methoxyphenyl
- dichloro
- alkoxy
- Prior art date
Links
- -1 2,4-dichloro-5-methoxyphenyl Chemical group 0.000 title 1
- 208000037906 ischaemic injury Diseases 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62128004P | 2004-10-22 | 2004-10-22 | |
| EP05820982A EP1802581B1 (en) | 2004-10-22 | 2005-10-21 | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury |
| PCT/US2005/037839 WO2006047262A1 (en) | 2004-10-22 | 2005-10-21 | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1802581T3 true PL1802581T3 (pl) | 2008-09-30 |
Family
ID=35784691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05820982T PL1802581T3 (pl) | 2004-10-22 | 2005-10-21 | 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-alkoksy-7-etynylo-3-chinolinokarbonitryle do leczenia urazów niedokrwiennych |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060116375A1 (enExample) |
| EP (1) | EP1802581B1 (enExample) |
| JP (1) | JP2008517924A (enExample) |
| KR (1) | KR20070085413A (enExample) |
| CN (1) | CN101044117A (enExample) |
| AT (1) | ATE391122T1 (enExample) |
| AU (1) | AU2005299822A1 (enExample) |
| BR (1) | BRPI0516995A (enExample) |
| CA (1) | CA2581807A1 (enExample) |
| CR (1) | CR9072A (enExample) |
| DE (1) | DE602005005843T2 (enExample) |
| DK (1) | DK1802581T3 (enExample) |
| EC (1) | ECSP077385A (enExample) |
| ES (1) | ES2303287T3 (enExample) |
| IL (1) | IL182547A0 (enExample) |
| MX (1) | MX2007004833A (enExample) |
| NO (1) | NO20071708L (enExample) |
| PL (1) | PL1802581T3 (enExample) |
| PT (1) | PT1802581E (enExample) |
| RU (1) | RU2007111704A (enExample) |
| SI (1) | SI1802581T1 (enExample) |
| WO (1) | WO2006047262A1 (enExample) |
| ZA (1) | ZA200703275B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| CN102952037A (zh) * | 2012-11-18 | 2013-03-06 | 大连九信生物化工科技有限公司 | 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法 |
| CN103848785B (zh) * | 2012-12-04 | 2016-07-13 | 上海医药集团股份有限公司 | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 |
| CN114436851B (zh) * | 2022-01-17 | 2023-08-22 | 常州大学 | 一种n,n-二甲基苄胺及其衍生物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| TW200423938A (en) * | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
-
2005
- 2005-10-21 CA CA002581807A patent/CA2581807A1/en not_active Abandoned
- 2005-10-21 EP EP05820982A patent/EP1802581B1/en not_active Expired - Lifetime
- 2005-10-21 WO PCT/US2005/037839 patent/WO2006047262A1/en not_active Ceased
- 2005-10-21 RU RU2007111704/04A patent/RU2007111704A/ru not_active Application Discontinuation
- 2005-10-21 CN CNA2005800360383A patent/CN101044117A/zh active Pending
- 2005-10-21 US US11/255,556 patent/US20060116375A1/en not_active Abandoned
- 2005-10-21 PL PL05820982T patent/PL1802581T3/pl unknown
- 2005-10-21 MX MX2007004833A patent/MX2007004833A/es active IP Right Grant
- 2005-10-21 ES ES05820982T patent/ES2303287T3/es not_active Expired - Lifetime
- 2005-10-21 AT AT05820982T patent/ATE391122T1/de not_active IP Right Cessation
- 2005-10-21 DK DK05820982T patent/DK1802581T3/da active
- 2005-10-21 JP JP2007538054A patent/JP2008517924A/ja not_active Withdrawn
- 2005-10-21 DE DE602005005843T patent/DE602005005843T2/de not_active Expired - Lifetime
- 2005-10-21 SI SI200530255T patent/SI1802581T1/sl unknown
- 2005-10-21 AU AU2005299822A patent/AU2005299822A1/en not_active Abandoned
- 2005-10-21 KR KR1020077011472A patent/KR20070085413A/ko not_active Withdrawn
- 2005-10-21 PT PT05820982T patent/PT1802581E/pt unknown
- 2005-10-21 BR BRPI0516995-0A patent/BRPI0516995A/pt not_active IP Right Cessation
-
2007
- 2007-03-30 NO NO20071708A patent/NO20071708L/no not_active Application Discontinuation
- 2007-04-11 EC EC2007007385A patent/ECSP077385A/es unknown
- 2007-04-12 IL IL182547A patent/IL182547A0/en unknown
- 2007-04-20 ZA ZA200703275A patent/ZA200703275B/xx unknown
- 2007-04-20 CR CR9072A patent/CR9072A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CR9072A (es) | 2007-09-07 |
| HK1104555A1 (en) | 2008-01-18 |
| WO2006047262A1 (en) | 2006-05-04 |
| DE602005005843D1 (de) | 2008-05-15 |
| PT1802581E (pt) | 2008-06-03 |
| NO20071708L (no) | 2007-07-13 |
| US20060116375A1 (en) | 2006-06-01 |
| ES2303287T3 (es) | 2008-08-01 |
| SI1802581T1 (sl) | 2008-08-31 |
| EP1802581B1 (en) | 2008-04-02 |
| ATE391122T1 (de) | 2008-04-15 |
| JP2008517924A (ja) | 2008-05-29 |
| KR20070085413A (ko) | 2007-08-27 |
| CA2581807A1 (en) | 2006-05-04 |
| MX2007004833A (es) | 2007-05-16 |
| BRPI0516995A (pt) | 2008-09-30 |
| ECSP077385A (es) | 2007-05-30 |
| DE602005005843T2 (de) | 2009-05-14 |
| RU2007111704A (ru) | 2008-11-27 |
| ZA200703275B (en) | 2008-08-27 |
| CN101044117A (zh) | 2007-09-26 |
| EP1802581A1 (en) | 2007-07-04 |
| AU2005299822A1 (en) | 2006-05-04 |
| IL182547A0 (en) | 2007-09-20 |
| DK1802581T3 (da) | 2008-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2282B1 (en) | Oxazole derivatives | |
| MX2007005694A (es) | Nuevos derivados de betulina, preparacion y uso de los mismos. | |
| AP1541A (en) | New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors. | |
| HK1038564A1 (zh) | 用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮 | |
| MXPA05003193A (es) | Compuesto de adenina novedoso y uso del mismo. | |
| EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
| MX2012001313A (es) | Compuesto espirociclicos que contienen nitrogeno y su uso medicinal. | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| RU2013107007A (ru) | Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение | |
| WO2007122634A3 (en) | Pyrimidinediones as tyrosine kinase inhibitors | |
| TW200716084A (en) | Methods for treating sleep-wake disorders | |
| MXPA05008706A (es) | 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas. | |
| BRPI0409959A (pt) | uso de derivados de azetidinacarboxamida em terapia | |
| WO2006113552A8 (en) | Cyanoarylamines | |
| TW200727893A (en) | Methods for treating sexual dysfunction | |
| IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| TW200626158A (en) | Naphthaline derivatives | |
| ZA200703275B (en) | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury | |
| MX2009007040A (es) | Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular. | |
| NO20062255L (no) | 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML) | |
| CY1110950T1 (el) | Ενωσεις ιμιδαζολιδινονυλ αμινοπυριμιδινης για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| MXPA05011521A (es) | Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo. | |
| MX2009006634A (es) | Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer. | |
| MXPA05014127A (es) | Uso de derivados de biciclo[2.2.1]heptano para la preparacion de composiciones farmaceuticas neuroprotectoras. |